Table II.

Breast cancer patients.

	Stage at diagnosis	Type of surgery	Lymph nodal status	Type of ADJ therapy	Type of ADJ CHT	Hormonal therapy	Anti-ErbB2 therapy	ErbB2 positivity	Antigens	Dose of peptides (μg)	CD8 post vaccination	DTH (mts)	DFS (mts)	OS	Vaccination beginning	Current disease status (Jul 2015)
MA01	IIIC	Quadrantectomy + lymphadenectomy	Pos	RT + CHT	Cyclophosphamide + adriamycin (4 cycles) followed by paclitaxel (4 cycles)	No	No	2+	MUC1, ErbB2, CEA	100	ErbB2	NEG	119+	125+	Jul 2007	NED
MA02	IIA	Quadrantectomy + lymphadenectomy	Pos	RT + CHT	Cyclophosphamide + adriamycin (4 cycles) followed by paclitaxel (4 cycles)	No	No	2+	MUC1, ErbB2	100	NEG	NEG	103+	109+	Jun 2007	NED
MA03	IIIA	Quadrantectomy + lymphadenectomy	Pos	RT + CHT	Cyclophosphamide + adriamycin (4 cycles) followed by paclitaxel (4 cycles)	No	Yes	3+	MUC1, ErbB2	100	NEG	MUC1	78	110+	Feb 2008	NED
MA05	IA	Quadrantectomy + lymphadenectomy	Neg	RT + CHT	Cyclophosphamide + adriamycin (6 cycles)	Yes	Yes	3+	MUC1, ErbB2	500	NEG	NEG	104+	109+	Apr 2008	NED
MA07	IIIC	Radical mastectomy + lymphadenectomy	Pos	RT + CHT	Docetaxel + epirubicin + cyclophosphamide (6 cycles)	Yes	Yes	3+	MUC1, ErbB2, CEA	500	NEG	MUC1, CEA	97+	113+	Nov 2008	NED
MA08	IIA	Radical mastectomy + lymphadenectomy	Pos	No	-	Yes	No	3+	MUC1, ErbB2, CEA	500	NEG	NEG	111+	111+	Nov 2008	NED
MA010	IIA	Quadrantectomy + lymphadenectomy	Pos	RT + CHT	Cyclophosphamide + adriamycin (4 cycles) followed by paclitaxel (4 cycles)	No	No	2+	MUC1, ErbB2, CEA	500	CEA	NEG	89+	96+	Oct 2009	NED